Price transparency continues to plague healthcare, as this new report from Castlight Health suggests.
Healthcare price transparency continues to be an ongoing struggle for payers and patients. While grocery stores service competitive prices for a box of cereal, the variability in prices for the same healthcare service sees a huge differential. A new report released by Castlight Health underscores this problem, with the pricing of mammograms in 30 largest cities in the United States as a case study.
For the study, Castlight Health examined the pricing of OB/GYN follow-up visits, preventative gynecological exams, mammograms, and HPV tests across states, using medical claims data. Additionally, provider information, provider rate sheets (payer-provider negotiated rates), and some publicly available information was included in the data set. Employee out-of-pocket cost added to the amount paid by the employer was defined as the price of a service.
The results were astounding—a 44x variation in the cost of a mammogram across the 30 cities, ranging from $43 (Sarasota-Bradenton, FL) to $1898 (NY, Northern NJ, Long Island). The analysis notes that women in the larger metropolitan areas are charged exorbitantly higher—with huge price variations—for an important preventive test. While some cities included in the study (including Holland, MI; Sharon, PA; Columbia, MO; Daytona Beach, FL) had no price variation, some saw a variation that ranged from 2-fold (including Pittsburgh, PA and New Orleans, LA) to nearly 21-fold (Dallas-Fort Worth, TX) in the same city.
According to Jonathan Rende, chief research and development officer at Castlight Health, these findings speak to our broken healthcare system. “We’ve seen over the years that women are bigger consumers of health care than men in general and we wanted to drill into some of the more common services and see how those varied,” Rende said when speaking about their study.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More